Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hemay020
- Development stage
- Discontinued
- Lead developer
- Tianjin Hemay Biotech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Hemay020 is a small molecule antineoplastic drug that acts as an irreversible epidermal growth factor receptor (EGFR) antagonist. It was developed for the treatment of advanced malignant solid neoplasms, including non-small cell lung cancer and other solid tumors. The drug was originally developed by Tianjin Hemay Pharmaceutical Technology and Hainan General Sanyang Pharmaceutical. Its mechanism involves inhibiting EGFR signaling pathways, which are often dysregulated in various cancers. Clinical development reached phase 1 trials; however, these were terminated and there is no current evidence of ongoing clinical development or approval for any indication[2][4].
- Other names
- hemay020hemay-020hemay 020
02
Targets
Beyond the preview
Go deeper on hemay020.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hemay020.